ASP 3291

Drug Profile

ASP 3291

Alternative Names: ASP3291

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Telsar Pharma
  • Class Anti-inflammatories; Cyclic peptides
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 01 Apr 2014 Telsar Pharma completes a phase II trial in Ulcerative colitis in USA, Canada, Israel and Serbia (NCT01612039)
  • 17 Jan 2014 Telsar Pharma completes enrolment in its phase II trial for Ulcerative colitis in USA (NCT01612039)
  • 01 Jul 2012 Phase-II clinical trials in Ulcerative colitis in Canada, Israel and Serbia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top